| risperidone / Generic mfg. |
NCT01363349: Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia |
|
|
| Terminated | 2b | 269 | Europe, RoW | CYP-1020, BL-1020, Risperidone | BioLineRx, Ltd. | Schizophrenia, Cognitive Effect on Schizophrenic Patients | 03/13 | 04/13 | | |
|
NCT00921804: Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients |
|
|
| Completed | 2a | 296 | US | AZD 8529, Risperidone, Risperdal, Placebo to match AZD8529, Placebo to match risperidone | AstraZeneca | Schizophrenia | 05/10 | 05/10 | | |
NCT03055338: An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005) |
|
|
| Completed | 2a | 224 | US | MK-8189, Risperidone, Placebo matching MK-8189, Placebo matching risperidone | Merck Sharp & Dohme LLC | Schizophrenia, Acute Episode | 01/18 | 01/18 | | |
NCT03557931: A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication |
|
|
| Completed | 2a | 233 | US | ASP4345, placebo, risperidone, Risperdal, quetiapine, Seroquel, olanzapine, Zyprexa, ziprasidone, Geodon, aripiprazole, Abilify, brexpiprazole, Rexulti, paliperidone, Invega, lurasidone, Latuda | Astellas Pharma Global Development, Inc. | Schizophrenia | 10/19 | 10/19 | | |
2015-001916-37: The neuropsychological features of aggressive behaviour in children and adolescents with diagnosis of Conduct Disorder or Oppositional Defiant Disorder (CD/ODD) Caratteristiche neuropsicologiche del comportamento aggressivo in bambini e adolescenti con diagnosi di Disturbo della Condotta o Disturbo Oppositivo Provocatorio |
|
|
| | 2 | 160 | Europe | Film-coated tablet, Tablet, Capsule, hard, Modified-release capsule, hard, Risperdal, Abilify, Strattera, Medikinet | RADBOUD UNIVERSITY MEDICAL CENTER, 7PQ Unione Europea | Aggressive behavior in children and adolescents with Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD) Aggressività in bambini e adolescenti affetti da Disturbo della Condotta (CD) o Disturbo Oppositivo Provocatorio (ODD), Aggressive behavior in children and adolescents with a psychiatric diagnosis of Conduct Disorder or Oppositional Defiant Disorder Aggressività in bambini e adolescenti con diagnosi psichiatrica di Disturbo della Condotta o Disturbo Oppositivo Provocatorio, Psychiatry and Psychology [F] - Psychological processes [F02] | | | | |
NCT00000310: Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2 |
|
|
| Terminated | 2 | 0 | US | Risperidone | National Institute on Drug Abuse (NIDA), VA Boston Healthcare System | Cocaine-Related Disorders | 03/96 | 03/96 | | |
NCT00000342: Risperidone for the Treatment of Cocaine Dependence - 7 |
|
|
| Completed | 2 | 0 | US | Risperidone | National Institute on Drug Abuse (NIDA) | Cocaine-Related Disorders | 08/97 | 09/97 | | |
NCT00000347: Risperidone for Treatment of Cocaine Dependence in Outpatients - 12 |
|
|
| Completed | 2 | 0 | US | Risperidone | National Institute on Drug Abuse (NIDA) | Cocaine-Related Disorders | 08/98 | 09/98 | | |
NCT00000317: Early Phase II Trials for Cocaine Medication Development - 1 |
|
|
| Completed | 2 | 31 | US | Risperidone, Risperidal, Placebo, Relapse prevention counseling, RPT-CBT | New York State Psychiatric Institute, National Institute on Drug Abuse (NIDA), Research Foundation for Mental Hygiene, Inc. | Cocaine-Related Disorders, Substance-Related Disorders | 07/99 | 07/99 | | |
NCT00000309: Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1 |
|
|
| Terminated | 2 | 0 | US | Risperidone | Butler Hospital, National Institute on Drug Abuse (NIDA), VA Boston Healthcare System | Cocaine-Related Disorders | 01/00 | 01/00 | | |
NCT00004393: Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome |
|
|
| Completed | 2 | 50 | US | risperidone | National Center for Research Resources (NCRR), Yale University | Tourette Syndrome | | 09/00 | | |
NCT00000267: Risperidone Treatment in Dually-Diagnosed Individuals - 2 |
|
|
| Completed | 2 | 0 | US | Risperidone | National Institute on Drug Abuse (NIDA), New York State Psychiatric Institute | Cocaine-Related Disorders | | 12/01 | | |
| Completed | 2 | 231 | US | talnetant, risperidone | GlaxoSmithKline | Schizophrenia | 04/03 | 04/03 | | |
NCT00639483: Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia |
|
|
| Completed | 2 | 270 | Europe, RoW | Celecoxib, Placebo | Pfizer | Schizophrenia | | 01/04 | | |
NCT00073658: Treating Behavioral Disturbances in Individuals With Dementia |
|
|
| Completed | 2 | 137 | US | Citalopram, Risperidone | University of Pittsburgh, National Institute of Mental Health (NIMH) | Dementia | 06/05 | 06/05 | | |
NCT00000272: New Approaches to Cocaine Abuse Medications (B) - 7 |
|
|
| Completed | 2 | 0 | US | Risperidone | National Institute on Drug Abuse (NIDA), New York State Psychiatric Institute | Cocaine-Related Disorders, Substance-Related Disorders | | | | |
| Terminated | 2 | 90 | US | Risperidone, Paroxetine | Beth Israel Medical Center | Major Depressive Disorder With Panic Attacks, Panic Disorder | 07/05 | 07/05 | | |
NCT00202007: Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia |
|
|
| Completed | 2 | 240 | RoW | Aripiprazole tablet, 5-30mg/day, oral, 6 weeks, Risperidone tablet, 1-6mg/day, oral, 6 weeks | Otsuka Beijing Research Institute, Zhejiang Otsuka Pharmaceutical Co., Ltd. | Schizophrenia | | 07/05 | | |
NCT00300963: Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients |
|
|
| Completed | 2 | 275 | US | Talnetant | GlaxoSmithKline | Schizophrenia | 10/05 | 10/05 | | |
NCT00103727: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia |
|
|
| Completed | 2 | 282 | US | Talnetant, placebo, risperidone | GlaxoSmithKline | Schizophrenia | 10/05 | 10/05 | | |
NCT00073164: Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia |
|
|
| Completed | 2 | 400 | US | Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone | Abbott | Schizophrenia | | | | |
NCT00361166: Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone |
|
|
| Completed | 2 | 400 | US, RoW | ACP-103 | ACADIA Pharmaceuticals Inc. | Schizophrenia | | 03/07 | | |
| Completed | 2 | 338 | US, Europe, RoW | SB-773812, Olanzapine | GlaxoSmithKline | Schizophrenia | | 08/07 | | |
NCT00284206: A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence |
|
|
| Completed | 2 | 20 | US | long-acting injectable risperidone | Seattle Institute for Biomedical and Clinical Research, Janssen, LP | Methamphetamine Dependence | 08/07 | 08/07 | | |
NCT00563706: Study Evaluating Vabicaserin in Subjects With Schizophrenia |
|
|
| Completed | 2 | 199 | US, Canada | vabicaserin, risperidone, placebo | Pfizer | Schizophrenia | 06/08 | 06/08 | | |
NCT00722176: Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 |
|
|
| Completed | 2 | 220 | US | BL-1020, BL-1020 10-30 mg, BL-1020 High Dose, risperidone | BioLineRx, Ltd. | Schizophrenia | 07/09 | 12/09 | | |
NCT00567710: A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study |
|
|
| Completed | 2 | 360 | US | BL - 1020, Placebo, Risperidone | BioLineRx, Ltd. | Schizophrenia | 07/09 | 09/09 | | |
|
|
NCT00768612: Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia |
|
|
| Withdrawn | 2 | 0 | Japan | SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day, Risperidone 4mg/day | Wyeth is now a wholly owned subsidiary of Pfizer | Schizophrenia | 07/09 | 07/09 | | |
NCT00694707: Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia |
|
|
| Completed | 2 | 732 | US, RoW | Placebo, Cariprazine, RGH-188, Risperidone, Risperdal | Forest Laboratories, Gedeon Richter Ltd. | Schizophrenia | 08/09 | 08/09 | | |
|
CONNECT, NCT00439634: Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia |
|
|
| Terminated | 2 | 873 | US, Canada | AVE1625, Drinabant, placebo | Sanofi | Schizophrenia | 09/09 | 09/09 | | |
| Completed | 2 | 124 | Europe, RoW | Lu AE58054, Placebo | H. Lundbeck A/S | Schizophrenia, Cognition | 01/10 | 02/10 | | |
CSP #504, NCT00099983: Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder |
|
|
| Completed | 2 | 296 | US | Risperidone, Risperdal, Placebo, Suger Pill | US Department of Veterans Affairs, Janssen, LP | Stress Disorders, Post-Traumatic | 02/10 | 01/11 | | |
| Completed | 2 | 261 | Europe, US, RoW | LY2140023, pomaglumetad methionil, aripiprazole, Abilify, olanzapine, Zyprexa, risperidone, Risperdal | Denovo Biopharma LLC | Schizophrenia | 05/10 | 12/10 | | |
|
|
| Unknown status | 2 | 50 | RoW | MS14, Risperidone | Farzan Institute | Schizophrenia | 10/10 | 04/11 | | |
STAR-1, NCT00509067: Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia |
|
|
| Completed | 2 | 43 | US | Galantamine, Razadyne, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole | Georgetown University, National Institute of Mental Health (NIMH), Washington D.C. Veterans Affairs Medical Center | Schizophrenia | 03/11 | 03/11 | | |
NCT01175135 / 2010-020764-38: An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia |
|
|
| Completed | 2 | 259 | US, Europe, RoW | PF-02545920, Placebo, Risperidone, Risperdal | Pfizer | Schizophrenia | 08/11 | 08/11 | | |
| Completed | 2 | 880 | US, RoW | Risperidone, Placebo, LY2140023 | Eli Lilly and Company | Schizophrenia | 05/12 | 05/12 | | |
|
2009-017852-28: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 versus Placebo in Patients with DSM-IVTR Schizophrenia |
|
|
| Completed | 2 | 880 | Europe | LY2140023, Risperidone, LY2140023, Tablet, Capsule, hard, Risperidone | Eli Lilly and Company | Schizophrenia | | | | |
| Completed | 2 | 7 | Europe | Pipamperone, Risperdal, Invega and Xeplion, Placebo | PharmaNeuroBoost N.V. | Chronic Schizophrenia, Schizoaffective Disorder | 11/12 | 12/12 | | |
NCT01272765: Anti-psychotic Medication (Stable Dose) Weight Loss Study |
|
|
| Withdrawn | 2 | 0 | US | Placebo, sugar pill, IHBG-10, IHBG10 | Avera McKennan Hospital & University Health Center | Obesity | 01/13 | 01/13 | | |
NCT01499563: Study of a Novel Antipsychotic ITI-007 in Schizophrenia |
|
|
| Completed | 2 | 335 | US | ITI-007, Placebo, Risperidone | Intra-Cellular Therapies, Inc. | Schizophrenia | 08/13 | 11/13 | | |
|
|
|
NCT01623713: Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia |
|
|
| Completed | 2 | 260 | RoW | iloperidone, Risperidone | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Schizophrenia, Iloperidone, Efficacy | 10/13 | 11/13 | | |
NCT01272752: Anti-psychotic Medication (New Use) Weight Loss Study |
|
|
| Withdrawn | 2 | 0 | US | IHBG-10, IHBG10, Placebo, sugar pill | Avera McKennan Hospital & University Health Center | Obesity | 12/13 | 12/13 | | |
| Completed | 2 | 12 | US | Risperidone + Desipramine, Norpramin | Dartmouth-Hitchcock Medical Center, University of South Carolina, University of Massachusetts, Worcester, Michigan State University | Schizophrenia, Alcoholism, Dual Diagnosis | 08/14 | 09/14 | | |
2005-000016-27: Safety and efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms:A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, controlled study. |
|
|
| | 2 | 50 | Europe | Risperidone, S33138-F34, S33138-F35, RISPERDAL, RISPERDAL | Institut de Recherches Internationales Servier, Laboratorios Servier S.L. (For Spain only), SERVIER Research and Development ICTR (For United Kingdom only), INSTITUT DE RECHERCHES INTERNATIONALES SERVIER, | Schizophrenia | | 10/06 | | |
2006-004783-31: A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of AZD3480 in Schizophrenic Patients on Stable Antipsychotic Monotherapy with quetiapine, risperidone or olanzapine |
|
|
| Ongoing | 2 | 50 | Europe | AZD3480, | AstraZeneca AB | Schizophrenia | | | | |
NCT02462473: A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry |
|
|
| Terminated | 2 | 9 | US | Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone | Janssen Research & Development, LLC | Schizophrenia, Schizoaffective Disorder | 01/16 | 01/16 | | |
ProjectV, NCT01171937: Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior |
|
|
| Completed | 2 | 41 | US | Risperidone, Risperdal, Placebo, Inactive medicine | University of California, Los Angeles, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Autism | 09/16 | 12/16 | | |
ACTRN12616000178448: Clozapine and risperidone for the treatment of progressive multiple sclerosis (CRISP) |
|
|
| Terminated | 2 | 36 | | | Victoria University of Wellington, Ministry for Business, Innovation, and Employment | progressive multiple sclerosis | | | | |
NCT02658357: Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant |
|
|
| Completed | 2 | 66 | US | Risperidone Implant | Braeburn Pharmaceuticals | Schizophrenia, Schizo-affective Disorder | 08/17 | 08/17 | | |
NCT02875340: A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Completed | 2 | 8 | NA | VAL401, Risperidone lipid formulation | ValiSeek Limited | Carcinoma, Non-Small-Cell Lung, Adenocarcinoma | 09/17 | 09/17 | | |
| Completed | 2 | 80 | NA | Risperidone, Resperidal, hyperbaric oxygen therapy, Non specific Multivitamin | Minia University | Autism Spectrum Disorder | 01/18 | 12/18 | | |
NCT04567524: A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules |
|
|
| Completed | 2 | 34 | US | LYN-005, Risperidone | Lyndra Inc., Worldwide Clinical Trials | Schizophrenia Schizoaffective | 12/20 | 12/20 | | |
2020-000094-24: A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia |
|
|
| Ongoing | 2 | 576 | Europe, RoW | Risperidone, MK-8189, Tablet, Capsule, Risperdal (Risperdione) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT04512066: A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 2 | 287 | Japan, US, RoW | RO6889450, Placebo, Risperidone | Hoffmann-La Roche | Schizophrenia, Schizoaffective Disorder | 06/22 | 06/22 | | |
CLOZ-AID, NCT04529226: Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis |
|
|
| Active, not recruiting | 2 | 75 | Europe | Clozapine, Nemex, Leponex, haloperidol, pimozide, olanzapine, risperidone, amisulpride | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Psychosis, Intellectual Disability | 01/25 | 12/25 | | |
NCT04201834: Risperidone for the Treatment of Huntington's Disease Involuntary Movements |
|
|
| Completed | 2 | 5 | US | Risperidone, BioStamp nPoint device | University of Rochester | Huntington Disease, Chorea | 12/23 | 12/23 | | |
| Active, not recruiting | 2 | 500 | Europe, Japan, US, RoW | MK-8189, Risperidone, Placebo to MK-8189, Placebo to risperidone | Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Schizophrenia | 07/24 | 07/24 | | |
NCT04105231: Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use |
|
|
| Recruiting | 2 | 130 | Europe | Cannabidiol, Epidiolex, Risperidone, Risperidon | Lone Baandrup, Danish Center for Sleep Medicine, Copenhagen University Hospital, Denmark, Glostrup University Hospital, Copenhagen, University of Copenhagen | Dual Diagnosis | 12/24 | 06/25 | | |
| Recruiting | 2 | 60 | Canada | Psilocybin 25 mg, Risperidone 1 MG, Placebo | Centre for Addiction and Mental Health | Treatment-resistant Depression | 02/26 | 02/26 | | |
OCD-RT, NCT05401019: Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD) |
|
|
| Not yet recruiting | 2 | 52 | NA | Pramipexole, Risperidone | Clinical Academic Center (2CA-Braga), University of Minho | Obsessive-Compulsive Disorder | 12/26 | 12/26 | | |
NCT00653406: A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients |
|
|
| Completed | 1/2 | 29 | Japan | Risperidone long acting injectable | Janssen Pharmaceutical K.K. | Schizophrenia | | 10/03 | | |
NCT01282632: Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression |
|
|
| Completed | 1/2 | 42 | Canada | Risperidone, Olanzapine | Sunnybrook Health Sciences Centre | Subjects Had Unipolar, Non-psychotic Major Depression | 03/04 | 03/04 | | |
NCT00166595: Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD) |
|
|
| Completed | 1/2 | 100 | US | Risperidone | Children's Hospital Medical Center, Cincinnati, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Child Development Disorders, Pervasive | | 03/05 | | |
NCT00133822: Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial |
|
|
| Completed | 1/2 | 65 | US | Sertraline and Risperidone | Emory University, Janssen, LP | Post-Traumatic Stress Disorders | 09/06 | 09/06 | | |
| Completed | 1/2 | 21 | NA | Risperidone, Placebo | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Schizotypal Personality Disorder | 01/14 | 01/15 | | |
| Withdrawn | 1/2 | 0 | US | Risperidone plus Placebo, Risperdal, Risperidone plus DMXB-A | VA Office of Research and Development, University of Colorado, Denver | Schizophrenia | 08/16 | 08/16 | | |
NCT02650102: The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment |
|
|
| Unknown status | 1/2 | 200 | RoW | Risperidone, Risperdal, Olanzapine, Zyprexa, Quetiapine, Seroquel, Aripiprazole, Abilifya, Ziprasidone, Geodon | Shanxi Medical University | Schizophrenia | 12/16 | 12/16 | | |
